AbbVie-allied ADARx aims for IPO with 3 drugs in the clinic

RNA interference company ADARx Pharmaceuticals revealed its intentions to go public in a Friday night SEC filing, trying to take advantage of the industry's IPO momentum. The San Diego biotech plans to list on the ...